Baylor College of Medicine

ORIN1001-001: A Dose Escalation Study of Oral ORIN001 with and without Chemotherapy in the Treatment of Solid Tumors (H-45733)

Description

Content

This study is being done to learn more about the safety and effectiveness of an investigational oral medication called ORIN1001 for people with advanced solid tumors or metastatic breast cancer (triple-negative or ER-positive/HER2-negative) for which no effective standard treatments are available.

In the Phase 1 part of the study, ORIN1001 will be tested at different doses and possibly different schedules to find the safest dose. In the Phase 2 part of the study, some patients will receive ORIN1001 alone (at the dose determined in the Phase 1 part of the study) or in combination with Abraxane (chemotherapy).

Contact

Claudette Foreman

Phone 1: 713–798–7315

IRB: H-45733

Status:

Active

Created:

Back to topback-to-top